Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Formation of the floating thrombi of the thoracic aorta in a patient with JAK2 positive myeloproliferative neoplasm during therapy with direct oral anticoagulant (CROSBI ID 282036)

Prilog u časopisu | prikaz, osvrt, kritika | međunarodna recenzija

Vujaklija Brajković, Ana ; Peklic, Marina ; Grgic Medic, Marijana ; Vrkic Kirhmajer, Majda ; Vrhovac, Radovan ; Radonic, Radovan Formation of the floating thrombi of the thoracic aorta in a patient with JAK2 positive myeloproliferative neoplasm during therapy with direct oral anticoagulant // Gazzetta medica italiana. Archivio per le scienze mediche, 178 (2019), 11; 901-904. doi: 10.23736/s0393-3660.18.03991-8

Podaci o odgovornosti

Vujaklija Brajković, Ana ; Peklic, Marina ; Grgic Medic, Marijana ; Vrkic Kirhmajer, Majda ; Vrhovac, Radovan ; Radonic, Radovan

engleski

Formation of the floating thrombi of the thoracic aorta in a patient with JAK2 positive myeloproliferative neoplasm during therapy with direct oral anticoagulant

Floating thrombi in the aorta are very rare and usually associated with coagulation disorder. We report a patient with longstanding, relatively good controlled myeloproliferative neoplasm (MPN) who developed floating thrombi in the thoracic aorta while taking dabigatran etexilate for thromboprophylaxis of atrial fibrillation (AF). Treatment with low molecular weight heparin was successful as patient recovered completely and control CTA showed complete resolution of the thrombi. To our knowledge, this is the first case of aortic thrombi that occurred despite dabigatran use. This raises concern that DOACs might not be efficient therapy for patients with myeloproliferative neoplasms. Another question is whether patients with polycythemia vera should continue the use of acetylsalicylic acid when anticoagulant drug is needed.

Thrombosis ; Aorta ; Myeloproliferative disorders ; Dabigatran

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

178 (11)

2019.

901-904

objavljeno

0393-3660

1827-1812

10.23736/s0393-3660.18.03991-8

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost